HAO ZHANG

Partner·Shanghai

+86 21 6263 5917

hao.zhang@fangdalaw.com

PRACTICE AREA

MR. HAO ZHANG SPECIALIZES IN M&A, PRIVATE EQUITY INVESTMENT, FOREIGN DIRECT INVESTMENT, AND GENERAL CORPORATE MATTERS.

Education

- Fudan University School of Law, LL.B., 2009
- New York University School of Law, LL.M., 2015

Professional Qualification

- Admitted to practice in the PRC
- Admitted to practice in New York

Professional Background

- Mr. Zhang joined the firm in 2019. Before joining Fangda, Mr. Zhang worked at several leading international and PRC law firms in their Shanghai and Beijing offices.

REPRESENTATIVE MATTERS AND CASES

- Represented SoftBank Vision Fund in its investment in Didi Chuxing, one of the largest app-based transportation companies headquartered in China
- Represented SoftBank Vision Fund in its investment in the China piece of OYO Rooms, the world's third-largest and fastest-growing hospitality chain of leased and franchised hotels and homes
- Represented SoftBank Vision Fund in series D+ investment in Beike, a leading app-based real estate brokerage service and financial services provider in China
- Represented SoftBank Vision Fund in its Series C investment in Ziroom, a leading service provider of long- and short-term lease of renovated apartments
- Represented Yunfeng Capital in its equity investment in a China internet-based insurance brokerage service provider
- Represented TPG Capital in its proposed investment in a domestic e-commerce logistics company in Shanghai
- Represented Colgate-Palmolive in its proposed acquisition of 75% equity interest in a leading personal oral care company in China
- Represented Nouryon (formally AkzoNobel Specialty Chemical) in its acquisition of a China-based chemical product manufacturer
- Represented Axalta Coating Systems in its acquisition of a China-based coatings company
- Represented Pall Corporation, a subsidiary of Danaher Corporation, in its disposal of water purification system businesses
- Represented Jamieson Laboratories, one of the largest nutritional food manufacturers and distributors in Canada, in its joint venture in China
- Represented VMware in its investment in and business operation with a domestic cloud solution provider in China
- Represented a California-based biotech company in its joint venture in China for CAR-T immunotherapies treatment business
- Represented Morgan Stanley Real Estate Fund in its indirect acquisition of a logistics park in Dongguan through its direct acquisition of a warehousing company in Dongguan
- Represented GLP in its indirect acquisition of a logistics real property in Tianjin Free Trade Zone through its

direct acquisition of a logistics company in Tianjin

- Represented KHI Overseas Limited in its indirect acquisition of Crystal Galleria, a Grade-A office tower in Jing'an District, Shanghai, through its direct acquisition of a majority interest in an offshore subsidiary of Shenzhen World Union (002285.SZ)
- Represented China National Biotech Group in its proposed bid to acquire a leading Israel-based aesthetic medical device manufacturer
- Represented a Beijing-based private equity firm in its proposed $148 million asset acquisition of the physical vapor deposition business unit of Praxair, Inc.